TMRW, the creator of the first Robotic Process Automation (RPA) platform designed specifically for in vitro fertilization (IVF), has raised over $12M in Series A financing alongside significant additions to its corporate, scientific and advisory boards.
TMRW Life Sciences LLC, was founded in 2018 and in headquartered in New York City. In coming decades, a rapidly scaling fertility industry and increased access to IVF therapies will be responsible for nearly 300 million global births — almost all of which will rely upon frozen fertility cells.
Already experiencing rapid market adoption by leading U.S. clinics, TMRW’s RPA platform is poised to become the global standard. IVF clinicians have embraced TMRW’s platform because it replaces an outdated analog IVF cryo-management function with proven risk-mitigating RPA technology. Current TMRW clinic partners represent almost 20% of total U.S. fertility cycles.
TMRW’s integrated platform provides the world’s first complete radio-frequency identification (RFID), cryo-temperature compatible digital chain of custody for all fertility cells—including eggs and embryos. TMRW software is constantly vigilant and automates 17,000 daily environmental “health checks” that ensure the safety, and security of the world’s most precious cells.
The Series A was led by Special Situations’ Life Sciences Innovation (LSI) Fund, the first venture vehicle focused on next generation solutions for the fertility industry. TMRW is one of the fund’s first investments and its Managing Director, David Sable, M.D. has joined TMRW’s Scientific Advisory Board. Other Series A participants include the family office of noted investor and philanthropist Glenn Dubin as well as several other private commitments. TMRW’s co-founders, Joshua Abram, Alan Murray and Jeff Port, M.D. are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion.
Alongside the completion of Series A financing, TMRW has expanded its corporate and scientific advisory boards. In addition to Dr. Sable, TMRW also appointed Andrew Brooks, Ph.D., currently the Chief Operating Officer of the RUCDR Infinite Biologics at Rutgers University, the largest academically affiliated biorepository in the world, to the Chairmanship of TMRW’s Scientific Advisory Board. A molecular neuroscientist, Brooks has deep experience in advising leading U.S. and global institutions in Europe, Asia and the Middle East on topics related to cryo-biology. At the request of the government of Qatar, he has been long involved in the region’s pathbreaking Qatar Biobank and Genome Projects.
TMRW also appointed Tara Comonte and Robbie Myers as Independent Corporate Board Directors. Comonte is currently the Chief Financial Officer at Shake Shack, overseeing all aspects of Finance and Technology as the company continues to expand at a rapid pace in both the US and across the globe. Myers served for 18 years as Editor-in-Chief of ELLE, the number one fashion magazine in the world, and led the brand to unprecedented success and growth.
“Our Life Sciences Innovation Fund invests in companies that will lead the expansion and growth in assisted reproductive technology.” … “With its advanced technology, TMRW can make IVF safer, more accessible and more affordable, both in the United States and worldwide. TMRW’s platform provides a necessary and elegant solution for clinics that are seeing an enormously growing demand to safely preserve vitrified cells.” – David Sable, M.D., Managing Director, Special Situations’ LSI Fund
“Fertility and population experts agree that by the end of the century, over 200 million people will be born through IVF. TMRW is committed to advancing technology that ensures this extraordinary demand can be safely met by fertility clinicians.” … “This capital will help us refine our technology, further expand our board and executive leadership team and make our technology available to fertility clinics worldwide.” – Joshua Abram, co-founder of TMRW